Cardiovascular Improvements With MV ASV Therapy in Heart Failure

NATerminatedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Acute Decompensated Heart FailureSleep Disordered Breathing
Interventions
DEVICE

MV ASV

Minute ventilation-targeted servo-ventilation therapy.

DRUG

Optimized Medical Treatment

Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated

Trial Locations (15)

17033

Penn State Hershey, Hershey

19107

Jefferson Heart Institute, Philadelphia

21201

University of Maryland, Baltimore

23507

Sentara Cardiovascular Research Institute, Norfolk

27710

Duke University Medical Center, Durham

31201

Mercer University, Macon

35801

The Heart Center, Huntsville

45267

University of Cincinnati, Cincinnati

60611

Northwestern University, Chicago

63110

Washington University School of Medicine, St Louis

64111

St. Luke's Hospital of Kansas City, Kansas City

80220

VA Medical Center, Denver

90073

VA Greater Los Angeles Healthcare System, Los Angeles

98195

University of Washington, Seattle

Unknown

Heart and Diabetes Center - North Rhine-Westphalia (HDZ-NRW), Bad Oeynhausen

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

ResMed Foundation

OTHER

lead

ResMed

INDUSTRY

NCT01953874 - Cardiovascular Improvements With MV ASV Therapy in Heart Failure | Biotech Hunter | Biotech Hunter